GLP-1 proved the science could work. The harder test began once patients tried to get it.

In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy.

The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive.

And for many patients, the answer depends on which door is actually open.

Timestamps

• 00:06  When the Prescription Isn’t Enough
• 07:47  How Compounding Became the Workaround
• 10:58  Why Coverage Still Creates Friction
• 16:17  Public Coverage and International Contrasts
• 21:53  PBMs, Employers, and the Formulary Fight
• 28:56  Cash Pay, TrumpRx, and New Access Lanes
• 35:19  The Pipeline Keeps Moving
• 35:48  Who Pays for Prevention?